GALDERMA
Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic dermatitis.
This study is a randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis.
Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that plays a key role in the pathogenesis of moderate-to-severe atopic dermatitis. Atopic dermatitis is a serious, chronic form of eczema associated with a high burden of disease linked to itch, sleep deprivation and significant quality of life impairment.
“We are advancing the development of nemolizumab as planned. The Phase 2 results showed clear clinical benefits, adding to the growing scientific evidence that the IL-31 pathway may be an important driver in atopic dermatitis. We are committed to continuing our work to bring new therapies to patients with moderate-to-severe atopic dermatitis,” said Thibaud Portal PhD, Galderma Global Vice President, Prescription medicines.
Earlier this year, Galderma presented the final results from the Phase 2b study of nemolizumab in patients with moderate-to-severe atopic dermatitis at the 2019 American Academy of Dermatology Annual Meeting late-breaking session and published in the Journal of Allergy and Clinical Immunology in August 20191
About the IL-31 Pathway and Atopic Dermatitis
Moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema, is a systemic inflammatory disease characterized by an allergic response driven by a subset of immune cells called Type 2 helper T cells, or Th2 cells. IL-31, a cytokine released by Th2 cells, is involved in AD associated pruritus by interacting with IL-31 receptor alpha expressed by neuron. IL-31 is also thought to play a role in AD skin inflammation and AD skin barrier impairment. Moderate-to-severe forms of AD can be characterized by pronounced cutaneous dryness, and skin lesions marked by redness, infiltration/papulation, crusting/oozing, and lichenification, with periods of lesion exacerbation accompanied by intense itching, scratching, and skin damage that can lead to secondary infections. Moderate-to-severe AD can negatively impact patients’ lives and is associated with a high burden to patients particularly with itching, sleep deprivation and depression.
About Nemolizumab
Nemolizumab, a first-in-class humanized monoclonal antibody, is directed against the IL-31R alpha, which blocks signaling from - IL-31. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
References
1. Silverberg JI, et al., Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus, Journal of Allergy and Clinical Immunology 2019, doi: https://doi.org/10.1016/j.jaci.2019.08.013 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005291/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“All Genetic Diseases Could be Cured within a Decade”, Hears Dubai Future Forum20.11.2025 14:15:00 CET | Press release
All known genetic diseases could be cured within the next decade thanks to major advances in gene editing, a leading scientist told the Dubai Future Forum 2025. Discussing his company’s research, Dr. Trevor Martin, Co-founder and CEO of Mammoth Biosciences, described “a one-time cure that will reshape the healthcare system as we know it.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120548681/en/ Dubai Future Forum 2025 (Photo: AETOSWire) Opening the forum, Khalfan Belhoul, CEO of Dubai Future Foundation, introduced the concept of “national cognitive potential”, arguing that countries in the future will gain a competitive edge in fields like AI by leveraging the collective cognitive strength of their societies. In another session, Dr. Nikku Madhusudhan, Professor of Astrophysics at the University of Cambridge, said there is a “good chance” humanity will discover life on another planet—possibly in the next decade. He exp
12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity20.11.2025 14:00:00 CET | Press release
How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/ Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers. The new face of fraud The identity threat landscape has entered a new industrial phase, defined by three structural shifts: Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own. Frau
Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies20.11.2025 14:00:00 CET | Press release
AI-driven genomic foundation model integrates wet-lab validation, population-scale genomics, and advanced machine learning to improve gene editing design at scale Founding team unites CRISPR pioneers and AI leaders, supported by a world-class Scientific Advisory Board including Dr. Vic Myer (former CTO, Editas Medicine) and Dr. Saar Gill (UPenn) Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies. Cassidy Bio’s AI-driven genomic foundation model combines proprietary wet-lab data, population-scale genomic insights, and advanced machine learning to predict the best pairings of guides, enzymes, and delivery modalities, matching t
Scientist.com Completes Acquisition by GHO Capital Partners to Accelerate Global R&D Orchestration20.11.2025 13:55:00 CET | Press release
Strategic partnership finalized, unlocking expanded AI-driven platform capabilities and international growth Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform, and GHO Capital Partners LLP (“GHO”), the specialist private equity investor in global healthcare, today announced the successful closing of GHO’s acquisition of Scientist.com. The transaction marks the beginning of an accelerated expansion phase, strengthening Scientist.com’s mission to transform pharmaceutical R&D by streamlining the entire outsourced research lifecycle. “This is a pivotal moment for Scientist.com and for the global research community we support,” said Kevin Lustig, CEO and Chris Petersen, CTO, the founders of Scientist.com. “Partnering with GHO, a team that shares our vision and brings deep expertise in scaling healthcare technology companies, enables us to invest aggressively in our AI-powered orchestration platform and expand our global footprint. Together, we are bet
SimpliStor™ Solid State Data Recorder Delivers High-Speed, Radiation-Tolerant Storage for Next-Generation Space Missions20.11.2025 13:00:00 CET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the SimpliStor™ Solid State Data Recorder (SSDR), a next-generation, radiation-tolerant data recorder that gives satellite operators, system integrators, and spacecraft designers a faster, smarter, and more resilient way to capture and protect mission-critical information in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120514203/en/ Frontgrade's SimpiStor™ 2.5TB Solid-State Data Recorder High-Throughput Performance SimpliStor delivers 2.5 terabytes of storage and 10Gbps throughput in a compact 3U SpaceVPX package, combining exceptional performance with low power consumption. Users can record more data in less time, with latency under 100 microseconds and continuous “store-to-full” recording, ensuring no data loss during peak operations. A 33-minute continuo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom